Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1002

1.

Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.

Matos JP, de Lourdes Rodrigues M, Ismerim VL, Boasquevisque EM, Genelhu V, Francischetti EA.

Clin Nephrol. 2005 Sep;64(3):180-9.

PMID:
16175942
3.

Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.

Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.

Nephrol Dial Transplant. 2006 Mar;21(3):683-9. Epub 2005 Dec 5.

4.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
5.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
6.

Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.

Sen S, Kanter M, Ustundag S, Aktas C, Dogutan H, Yalcin O.

Ren Fail. 2008;30(10):1023-33. doi: 10.1080/08860220802495248. Erratum in: Ren Fail. 2009;31(2):180. Saniye, Sen [corrected to Sen, Saniye]; Mehmet, Kanter [corrected to Kanter, Mehmet]; Sedat, Ustundag [corrected to Ustundag, Sedat]; Cevat, Aktas [corrected to Aktas, Cevat]; Omer, Yalcin [corrected to Yalcin, Omer].

PMID:
19016156
7.
8.

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

Nephrol Dial Transplant. 2000 Apr;15(4):487-97.

9.

Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.

Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.

Horm Metab Res. 2005 Apr;37 Suppl 1:4-8.

PMID:
15918104
10.

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.

Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH.

Nephrol Dial Transplant. 2002 Jun;17(6):1019-24.

11.

Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.

Fernandez Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernández Vega F, Tato A, Gutierrez E; PRONEDI Study Group.

Am J Kidney Dis. 2013 Feb;61(2):211-8. doi: 10.1053/j.ajkd.2012.07.011. Epub 2012 Aug 29.

PMID:
22939518
12.

Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.

Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B.

Scand J Urol Nephrol. 2005;39(6):511-7.

PMID:
16303729
13.
15.

[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].

Parving HH, Lehnert H, Brøchner-Mortensen J, Gomis R, Andersen S, Arner P.

Ugeskr Laeger. 2001 Oct 1;163(40):5519-24. Danish.

PMID:
11601118
16.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
17.

Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.

Dalla Vestra M, Simioni N, Masiero A.

Int Urol Nephrol. 2009;41(1):119-26. doi: 10.1007/s11255-008-9490-0. Epub 2008 Oct 29. Review.

PMID:
18958580
19.
20.

[The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].

Shamkhlova MSh, Trubitsyna NP, Katsaia GV, Goncharov NP, Malysheva NM, Il'in AV, Nikankina LV, Koshel' LV, Shestakova MV.

Ter Arkh. 2008;80(1):49-52. Russian.

PMID:
18326228
Items per page

Supplemental Content

Write to the Help Desk